The recombinant human parathyroid hormone, teriparatide as an alternative remedy for the medication-related osteonecrosis of the jaw
This article reviews the history of the anabolic effect of the low-dose rhPTH discovery, provides evidence-based data from animal and human studies, summarizes its biological mechanisms and the clinical benefits of the anabolic therapy and also their possible role in the management of MRONJ. The majority of the clinical data indicates that, in the case of therapy-resistant osteonecrosis, it may be worthwhile to apply short-term intermittent teriparatide therapy. Notwithstanding, more randomized clinical trials are necessary in order to confirm the efficacy and the safety of the use of teriparatide in the treatment of MRONJ...
Source: Orvosi Hetilap - September 11, 2023 Category: General Medicine Authors: Istv án Gera Nikolette Sz ücs Source Type: research
A Study on the Treatment Period and Bone Turnover Markers According to Application of Teriparatide in the Treatment of Medication-Related Osteonecrosis of the Jaw
The administration of teriparatide (TPTD) shows good clinical outcomes in previously refractory medication-related osteonecrosis of the jaws (MRONJ). Bone turnover markers, factors involved in bone formation and resorption, are used to measure the activity of bone metabolism and are an important factor that assesses the onset of MRONJ and the prognosis for treatment. (Source: Journal of Oral and Maxillofacial Surgery)
Source: Journal of Oral and Maxillofacial Surgery - September 1, 2023 Category: ENT & OMF Authors: Jun-Young Kim Source Type: research
Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study
ConclusionsSequential TPT + ZOL therapy is likely to increase bone mineralization at the lumbar level and to stabilize it at the femoral level, similarly to what obtained with the sequential TPT+Dmab. Both ZOL and Dmab are suggested to be effective sequential treatments after TPT. (Source: Endocrine)
Source: Endocrine - August 29, 2023 Category: Endocrinology Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
Longitudinal audit of outcomes subsequent to teriparatide therapy
Ir Med J. 2023 Aug 17;116(7):806.NO ABSTRACTPMID:37606211 (Source: Ir Med J)
Source: Ir Med J - August 22, 2023 Category: General Medicine Authors: S Rafferty U Bond E Dunlea M J Phelan L Harty Source Type: research
